JAK2 and atherosclerosis: Our studies demonstrate that TG101348 decreases atherosclerosis in Apoe−/− mice, likely by selective inhibition of hematopoietic JAK2 that results in suppression of excessive myelopoiesis driven by enhanced cell proliferation signaling in HSPCs and myeloid progenitors and reversal of HSPC expansion and leukocytosis.